Your AI-Trained Oncology Knowledge Connection!

ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care : Episode 15

Opinion

Video

February 28, 2025

Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches

Author(s):

Andrew Kuykendall, MD,Naseema Gangat, MBBS

Panelists discuss studies aimed at combating dose-dependent anemia as a consequence of Janus kinase inhibitors (JAKi) treatment and share their thoughts on potential strategies to address this challenge.

EP: 1.Initial Treatment Strategies for Polycythemia Vera

EP: 2.Cytoreductive Therapy in PV Treatment Paradigm

EP: 3.JAK Inhibition in Polycythemia Vera: Treatment Updates

EP: 4.Interferon Therapy in PV

EP: 5.Safety Considerations for PV Therapy

EP: 6.Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

EP: 7.Interferon Real- World Treatment Patterns in PV

EP: 8.Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks

EP: 9.Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024

EP: 10.An Overview to Myelofibrosis and Disease Risk

EP: 11.Treatment Goals for Myelofibrosis

EP: 12.Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials

EP: 13.Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib

EP: 14.Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

Now Viewing

EP: 15.Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches

EP: 16.Myelofibrosis at ASH 2024: Key Updates and Emerging Therapies

EP: 17.MPN Milestones of 2024 and What’s Next for 2025

Video content above is prompted by the following:

Dr Kuykendall to faculty: Dose-dependent anemia can be a consequence of treatment with JAKi. What are your thoughts on studies aimed at combating this challenge?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Apr 7th 2025 - Apr 8th 2026

online-activity

Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Apr 3rd 2025 - May 9th 2025

online-activity

Latest Conference Coverage

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches

EP: 1.Initial Treatment Strategies for Polycythemia Vera

EP: 2.Cytoreductive Therapy in PV Treatment Paradigm

EP: 3.JAK Inhibition in Polycythemia Vera: Treatment Updates

EP: 4.Interferon Therapy in PV

EP: 5.Safety Considerations for PV Therapy

EP: 6.Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

EP: 7.Interferon Real- World Treatment Patterns in PV

EP: 8.Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks

EP: 9.Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024

EP: 10.An Overview to Myelofibrosis and Disease Risk

EP: 11.Treatment Goals for Myelofibrosis

EP: 12.Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials

EP: 13.Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib

EP: 14.Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

EP: 15.Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches

EP: 16.Myelofibrosis at ASH 2024: Key Updates and Emerging Therapies

EP: 17.MPN Milestones of 2024 and What’s Next for 2025

Newsletter

Latest CME

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Wisconsin

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Indiana

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Wisconsin

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Indiana

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Wisconsin

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Indiana

Latest Conference Coverage